Takeda Selects Two New Partners for Annual Global Corporate Social Responsibility (CSR) Program to Support Strong Health Systems and Access to Healthcare in Developing Countries
11.6.2020 09:00:00 EEST | Business Wire | Press release
Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) today announced the addition of two partners to its Global Corporate Social Responsibility (CSR) Program, which makes long-term commitments to strengthen healthcare systems and improve access to healthcare for all in developing countries. As part of an annual decision-making process, Takeda employees worldwide have voted to add the Access to Health Fund and Bridges to Development as new partners for the Global CSR Program, which now supports 16 programs in more than 60 countries.
Takeda’s commitments to these new partner organizations in FY2020 include:
- JPY 1.1 billion (USD 10.1 million*) to Access to Health Fund to help build and improve community health centers and empower health staff from ethnic health organizations and ethnic community-based health organizations (EHOs/ECBHOs) in Myanmar’s Shan State to deliver quality health services, particularly for mothers and children, over the next 5 years.
- JPY 681 million (USD 6.3 million*) to Bridges to Development to eliminate or control 5 neglected tropical diseases in Papua New Guinea and Vanuatu including lymphatic filariasis, yaws, leprosy, trachoma, and soil-transmitted helminthiases. The 3-year project will improve health worker capacity, access to care and treatment.
“We welcome and very much value the interest that Takeda and its employees have shown in contributing to improving the health of vulnerable populations in conflict-affected and hard-to-reach areas in Shan State in Myanmar,” said Oren Ginzburg, Access to Health Fund Director.
“The Bridges team is thrilled to embark on this important work in service of communities and populations that have been frequently left behind,” said Julie Jacobson, Managing Partner & Co-Founder of Bridges to Development. “In this project, working with countries, we aim to achieve lasting health benefits through the elimination and control of several neglected tropical diseases in one innovative approach. We are thankful to Takeda employees who helped make this possible with their support.”
This year represents the 5th anniversary of Takeda’s Global CSR Program, which empowers employees in Takeda’s 80 countries of operation to be the decisionmakers for which innovative, high-impact activities receive the Company’s support. The Program, rooted in the company’s values, actively partners with world-class organizations and nongovernmental organizations (NGOs) with proven track records of addressing global health problems in effective, enduring ways to prevent disease, train health workers, strengthen supply chains, and improve access to quality diagnosis and treatment for patients worldwide.
“Since its launch in 2016, Takeda’s Global CSR Program has focused on initiatives that strengthen health systems and increase access across the patient journey in low- and middle-income countries. We’re expecting to reach at least 17 million beneficiaries through 2025 globally” said Takako Ohyabu, Chief Global Corporate Affairs Officer. “We are proud to partner with the Access to Health Fund and Bridges to Development as we strive to increase health worker capacity and preventive care for patients everywhere, ensure reliable access to essential equipment and supplies, and empower communities with knowledge, services, and access to care."
In less than five years, Takeda’s Global CSR Program partners have delivered transformational impact that serves communities worldwide today and will continue to contribute to better health outcomes and stronger health systems for years to come, including:
- JOICFP, Plan International, and UNICEF reached nearly 700,000 pregnant women and mothers, newborns, children, and adolescents, with quality health care, services, and education in sub-Saharan Africa and the Middle East.
- JOICFP, Plan International, Seed Global Health, and UNICEF in Africa and the Middle East, with World Vision in South Asia, have collectively trained approximately 6,000 health workers in 15 countries, including qualified nurses, midwives, and physician trainees, as well as community health workers and nutrition volunteers.
- Millions of children have been immunized against measles, and the capacity of trainings offered by academic and clinical institutions in sub-Saharan Africa has been expanded exponentially.
In line with Takeda’s core values and longstanding support for strong health systems and access to healthcare for all, Takeda recently announced contributions to the global COVID-19 response through three United Nations-led organizations to strengthen health systems, improve access to care and supplies, and address food insecurity.
Takeda also forges farsighted public-private philanthropic partnerships with game-changing multilateral and academic institutions worldwide, such as with The Global Fund to Fight AIDS, Tuberculosis and Malaria, and the London School of Hygiene & Tropical Medicine.
* Financial information relating to the donations has been converted from JPY to USD using the ¥108.87:$1 as of June 3, 2020. For the avoidance of doubt, the amounts payable as part of the donations are denominated in JPY.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200610005933/en/
Contact information
Takeda Pharmaceutical Company Limited
Ai Yoshikawa
+81(0)3-3278-3004
ai.yoshikawa@takeda.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,
DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 18:08:00 EEST | Press release
HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l
BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 202612.6.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early activity also seen in BTK inhibitor–naïve patients. These data are complemented by results from the all-oral combination of BRUKINSA® (zanubrutinib) plus next-generation BCL2 inhibitor BEQALZI™ (sonrotoclax; ZS), which continue to demonstrate rapid, deep, durable responses across multiple B-cell malignancies. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “BTK inhibition has reshaped the treatment of B-cell cancers, and we believe degradation is the next leap forwa
Cyviz: Microsoft’s Immersive Approach to Collaboration12.6.2026 10:00:00 EEST | Press release
Watch Video Case Study >> This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612831180/en/ Watch Video Case Study >> https://www.cyviz.com/case-studies/microsoft-immersive-suite/ As business and technology environments grow more complex, establishing shared understanding across disciplines has become critical. The Immersive Suite is designed for active collaboration, where visual narratives, data, and technical content are explored interactively. This allows participants to test scenarios, align perspectives, and move more efficiently from discussion to decision. “We deliberately work with familiar tools like PowerPoint. That allows us to focus on storytelling and interaction rather than explaining technology, making collaboration more natural and effective,” says Joris Haverkort, Chief Technology Officer for Microsoft Netherlands. A key principle is simplicity at scale. Instead of relying on specialized tools, users build co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
